Recombinant CD22 (Epratuzumab Biosimilar) anticorps

N° du produit ABIN5668216

Cet anticorps anti-CD22 (Epratuzumab Biosimilar) est un anticorps Human Monoclonal détectant CD22 (Epratuzumab Biosimilar) dans BP, FACS et IP. Adapté pour Humain, Cynomolgus et Macaque rhésus.

Aperçu rapide pour Recombinant CD22 (Epratuzumab Biosimilar) anticorps (ABIN5668216)

Antigène: CD22 (Epratuzumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain, Cynomolgus, Macaque rhésus

Hôte: Human

Clonalité: Monoclonal

Conjugué: Cet anticorp CD22 (Epratuzumab Biosimilar) est non-conjugé

Application: Blocking Peptide (BP), Flow Cytometry (FACS), Immunoprecipitation (IP)

Clone: HL22

Détail du produit anti-CD22 (Epratuzumab Biosimilar) anticorps

Fonction: Anti-CD22 [hL22 (Epratuzumab)], Human IgG1, kappa

Specificité: This antibody is specific for the 3rd Ig-like domain of human CD22 (epitope B), a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells.

Réactivité croisée: Cynomolgus, Macaque rhésus

Attributs du produit:

Original Species of Ab: Human

Original Format of Ab: IgG1

Purification: Protein A affinity purified

Pureté: > 98 % as determined by SDS-PAGE

niveau d'endotoxine: Endotoxin is < 1.0 EU/mg as determined by the LAL method

Immunogène: This antibody was prepared by the humanization of LL2 (EPB-2), a murine anti-CD22 IgG2a raised against Raji Burkitt lymphoma cells. Murine sequences comprise 5-10% of the molecule, with the remainder being human framework sequences, which greatly reduces the potential for immunogenicity (Traczewski, 2010).

Isotype: IgG1 kappa

Information d'application

Indications d'application: Epratuzumab binds to the third extracellular domain of CD22, inducing CD22 phosphorylation, resulting in negative modulation of BCR activation, and rapid CD22 internalization, leading to modulation of B-cell homing (Traczewski, 2010). Initial phase II and two terminated early phase III studies suggest that the use of this antibody to treat systemic lupus erythematosus is effective and well tolerated, but both phase III trials failed to meet primary clinical efficacy endpoints. Additionally, in vitro studies and clinical trials indicate that this antibody can be used in combination therapy with another inhibitor of B-cell activity, rituximab (anti-CD20), in the treatment of non-Hodgkin lymphoma (Traczewski, 2010).

Restrictions: For Research Use only

Stockage

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Détails sur CD22 (Epratuzumab Biosimilar)

Antigène: CD22 (Epratuzumab Biosimilar)

Classe de substances: Biosimilar

Sujet: Leu14, B-cell receptor CD22, B-lymphocyte cell adhesion molecule, BL-CAM, Sialic acid-binding Ig-like lectin 2, Siglec-2, T-cell surface antigen Leu-14

UniProt: P20273